Skip to main content
NFL Biosciences logo

NFL Biosciences — Investor Relations & Filings

Ticker · ALNFL ISIN · FR0014003XT0 LEI · 9695006VJWNTN4UNHA27 PA Professional, scientific and technical activities
Open in API
Filings indexed 184 across all filing types
Latest filing 2021-09-21 Investor Presentation
Country FR France
Listing PA ALNFL

About NFL Biosciences

https://www.nflbiosciences.com/

NFL Biosciences is a biopharmaceutical company that develops botanical drug candidates for the treatment of addictions. The company's lead product, NFL-101, is a nicotine-free drug candidate for smoking cessation derived from a protein extract of tobacco leaves. Its development pipeline also includes NFL-301, a candidate aimed at reducing excessive alcohol consumption. NFL Biosciences focuses on advancing its products through clinical trials with the goal of licensing them to pharmaceutical companies for commercialization.

Recent filings

Filing Released Lang Actions
NFL BIOSCIENCES : Accord de délivrance de son brevet aux États-Unis
Investor Presentation Classification · 98% confidence The document is an announcement from NFL BIOSCIENCES regarding the issuance of a patent (US 11123395) by the USPTO for their drug candidate NFL-101. The text focuses entirely on intellectual property protection, patent details, and its strategic importance for the company's future operations in key markets like the US. This clearly falls under the category of Intellectual Property (IP) documentation, as it details the protection granted for their innovation.
2021-09-21 French
NFL BIOSCIENCES: approval for its patent to be granted in the United States
Regulatory Filings Classification · 95% confidence The document announces that the United States Patent and Trademark Office (USPTO) issued a patent (US 11123395) for the company's drug candidate NFL-101. This is a specific announcement regarding intellectual property protection, which falls under the scope of legal or regulatory updates concerning the company's assets. While it relates to intellectual property, it is not a general legal proceeding (LTR) but a specific grant of rights. Given the options, this type of announcement about a specific legal/IP milestone that is not a standard financial report (10-K, IR, ER) or a director's dealing (DIRS) is best categorized as a general Regulatory Filing (RNS) or potentially an Intellectual Property filing (IP). Since 'IP' is defined as 'Investor Presentation', and this is clearly not a presentation, 'RNS' (Regulatory Filings - general regulatory announcements and fallback) is the most appropriate category for a specific, non-financial, non-management regulatory milestone announcement like a patent grant.
2021-09-21 English
NFL Biosciences : l’étude clinique de Phase II/III de NFL-101 pour le sevrage tabagique approuvée en France
Regulatory Filings Classification · 95% confidence The document is a press release from NFL Biosciences announcing the approval of its Phase II/III clinical trial (CESTO II) for NFL-101 by the French regulatory body (ANSM) and the Ethics Committee (CPP). This type of announcement, detailing clinical trial progress, regulatory milestones, and scientific objectives, does not fit neatly into the standard financial reporting categories (10-K, IR, ER, etc.). It is a specific operational update related to drug development. Since it is not a formal financial report, a management change, a dividend notice, or a proxy statement, and it is a specific regulatory/operational announcement, it best fits the general 'Regulatory Filings' (RNS) category as a catch-all for significant, non-standard corporate news, although 'LTR' (Legal Proceedings Report) is sometimes used for regulatory actions, this is about trial approval, not litigation. Given the options, RNS is the most appropriate fallback for a significant, non-financial regulatory/operational update.
2021-09-15 French
NFL BIOSCIENCES: Phase II/III clinical trial for NFL-101 for smoking cessation approved in Franc
Regulatory Filings Classification · 94% confidence The document announces the approval of a Phase II/III clinical trial (CEST0 II) for a drug candidate (NFL-101) by regulatory bodies (ANSM and CPP in France). It details the trial design, objectives, patient numbers, and the company's strategic outlook regarding this development. This content is a specific operational update related to drug development and regulatory milestones, which does not fit neatly into standard financial reports (10-K, IR, ER) or shareholder communications (DEF 14A, DIV). Since it is a significant announcement regarding the company's core operations (drug development) but is not a formal financial filing, it best fits the 'Regulatory Filings' (RNS) category as a general regulatory/operational announcement, or potentially a specialized 'Legal Proceedings Report' (LTR) if the focus was on litigation, but here it is about regulatory approval for a trial. Given the options, RNS serves as the best general regulatory announcement fallback for non-standard, material operational news that isn't explicitly covered elsewhere. It is not a Call Transcript (CT), Earnings Release (ER), or a formal financial report (IR/10-K).
2021-09-15 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.